Skip to main content

Closed

BTAI: BioXcel Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-71.7% / yr

Operating margin-7395.0%

ROIC-3439.5%

Financially safe

Stretched

Debt / equity-0.95×

Interest coverage-2.9×

Current ratio0.62×

BioXcel Therapeutics, Inc.

BTAINASDAQ Capital Market·USD·Closed

BioXcel Therapeutics, Inc.

BTAINASDAQ·USD·Closed

$0.81

+1.92%

$0.81

+$0.02 (1.92%)

52W Range

1thpctl

Volume

0.53×avg

Mkt Cap

24.95MUSD

P/E

-0.1TTM

Div Yield

–ann

52W Range

1thpctl

Volume

0.53×avg

Market Cap

24.95MUSD

P/E Ratio

-0.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings